What is the recommended management of side effects (immune‑related adverse events) in patients receiving nivolumab?

Management of Nivolumab Side Effects

For nivolumab-related immune adverse events, management is grade-dependent: continue therapy with monitoring for grade 1 toxicities (except neurologic, hematologic, cardiac), hold therapy and initiate corticosteroids for grade 2 toxicities, and permanently discontinue with high-dose corticosteroids for grade 3-4 toxicities (except controlled endocrinopathies). 1, 2

General Management Framework by Toxicity Grade

Grade 1 Toxicities

• Continue nivolumab with close monitoring 1, 2
• Initiate symptomatic treatment (acetaminophen, NSAIDs for pain/inflammation) 1
• Critical exceptions requiring immediate hold: any grade myocarditis, myasthenia gravis, Guillain-Barré syndrome, or severe hematologic toxicities 1, 2

Grade 2 Toxicities

• Hold nivolumab until symptoms improve to grade ≤1 1, 2
• Resume therapy only when on prednisone ≤10 mg/day 3, 1
• Initiate oral prednisone 10-20 mg/day for most organ toxicities 1
• For persistent symptoms after 4-6 weeks, escalate to grade 3 management 1
• Specialist referral indicated for inflammatory arthritis, persistent symptoms >4 weeks, or organ-specific concerns 1

Grade 3-4 Toxicities

• Permanently discontinue nivolumab (except for endocrinopathies stable on hormone replacement) 1, 2
• Initiate high-dose corticosteroids: prednisone 0.5-1 mg/kg orally or methylprednisolone 1-2 mg/kg IV 1
• Taper corticosteroids over minimum 4-6 weeks once symptoms resolve 1, 2
• Consider hospitalization for severe compromise 1

Organ-Specific Management

Colitis/Diarrhea (Most Common GI Toxicity)

Grade 1: Low-fiber diet, loperamide, continue nivolumab 4

Grade 2:

• Hold nivolumab 4
• Oral corticosteroids 4
• Flexible sigmoidoscopy/colonoscopy with biopsies mandatory for grade >1 diarrhea 4
• If non-responsive: vedolizumab or infliximab 4

Grade 3-4:

• Hospitalize, IV corticosteroids 4
• Infliximab is first-line for steroid-refractory acute severe colitis 4
• Vedolizumab alternative but slower response 4

Pneumonitis (Potentially Fatal)

Nivolumab causes pneumonitis in approximately 4% of patients 5. The median time to onset is 4.5 months 6.

Any grade pneumonitis:

• Hold nivolumab immediately 2
• High-resolution CT chest 2
• Consider bronchoscopy with BAL to exclude infection 2

Grade 2: Prednisone 1 mg/kg, hold therapy 2

Grade 3-4:

• Permanently discontinue nivolumab 2
• Methylprednisolone 2-4 mg/kg IV 2
• If steroid-refractory: consider infliximab, mycophenolate, or IVIG 2

Hepatitis

Grade 2 (ALT/AST 3-5× ULN):

• Hold nivolumab 1
• Monitor liver function tests every 3 days 1
• If worsening or not improving in 3-5 days: prednisone 0.5-1 mg/kg 1

Grade 3-4 (ALT/AST >5× ULN):

• Permanently discontinue nivolumab 1
• Prednisone 1-2 mg/kg 1
• If no improvement after 3 days: mycophenolate mofetil 1

Endocrinopathies

Hypothyroidism/Thyroiditis (occurs in 12% of patients) 6:

• Continue nivolumab - endocrinopathies do not require discontinuation 1, 2
• Initiate levothyroxine replacement 1
• Monitor TSH every 4-6 weeks 1

Hypophysitis:

• High-dose corticosteroids (prednisone 1-2 mg/kg) 1
• Hormone replacement as needed (cortisol, thyroid) 1
• May continue nivolumab once stable on replacement 1, 2

Arthritis/Inflammatory Arthropathy

Grade 1: Continue nivolumab, acetaminophen/NSAIDs 1

Grade 2:

• Hold nivolumab 1
• Prednisone 10-20 mg/day for 4-6 weeks 1
• Intra-articular corticosteroid injections for large joints 1
• Rheumatology referral if synovitis or symptoms persist >4 weeks 1

Grade 3-4:

• Hold nivolumab 1
• Prednisone 0.5-1 mg/kg 1
• If no improvement after 4 weeks: DMARDs (methotrexate, leflunomide) or biologics (TNF-α inhibitors, IL-6 inhibitors) 1
• Screen for hepatitis B/C and TB before DMARD initiation 1
• Avoid IL-6 inhibitors in patients with colitis (perforation risk) 1

Myositis (Potentially Fatal if Cardiac Involvement)

Any grade with elevated CK:

• Check troponin immediately to assess myocardial involvement 1
• ECG, echocardiogram 1
• Permanently discontinue if any cardiac involvement 1

Grade 2 (CK ≥3× ULN with weakness):

• Hold nivolumab 1
• Prednisone 0.5-1 mg/kg 1
• Neurology/rheumatology referral 1
• May require permanent discontinuation 1

Grade 3-4:

• Permanently discontinue nivolumab 1
• Methylprednisolone 1-2 mg/kg IV (or higher bolus if severe) 1
• If refractory after 4-6 weeks: IVIG, plasmapheresis, or additional immunosuppressants (methotrexate, azathioprine, mycophenolate) 1

Dermatologic Toxicities

Rash occurs in 21-28% of patients 6.

Grade 1-2: Topical corticosteroids, antihistamines, continue nivolumab 1

Grade 3: Hold nivolumab, oral prednisone 0.5-1 mg/kg 1

Severe reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis): Permanently discontinue, dermatology consultation, high-dose IV corticosteroids 1

Critical Monitoring Parameters

Baseline Assessment Before Each Infusion

• Complete blood count, comprehensive metabolic panel 1
• Liver function tests (AST, ALT, bilirubin, alkaline phosphatase) 1
• Thyroid function (TSH, free T4) every 6-12 weeks 1
• Creatinine, electrolytes 1

Patient Education Priorities

• Provide written materials on immune-related adverse events 3
• Instruct patients to report symptoms immediately to prevent grade 3 progression 3
• Emphasize unpredictable timing of toxicities (can occur weeks to months after starting therapy) 5

Special Considerations

Steroid-Refractory Cases

If no improvement after 3-5 days of high-dose corticosteroids or inability to taper below 10 mg prednisone after 3 months 1:

• Infliximab for colitis 4
• Mycophenolate mofetil for hepatitis 1
• IVIG or plasmapheresis for myositis 1

Resuming Nivolumab After Toxicity

• May resume for grade 2 toxicities once improved to grade ≤1 and prednisone ≤10 mg/day 3, 1
• Do not resume if: grade 3-4 toxicity (except endocrinopathies), any cardiac involvement, or recurrent grade 3 toxicity upon rechallenge 1, 2
• Decision should be multidisciplinary for GI toxicities given recurrence risk 4

Common Pitfalls

1. Delaying corticosteroids for grade 2-3 toxicities - early intervention prevents progression to life-threatening complications 1, 2
2. Rapid steroid taper - minimum 4-6 weeks required to prevent rebound 1, 2
3. Missing myocardial involvement in myositis - always check troponin with elevated CK 1
4. Continuing therapy with grade 2 pneumonitis - requires immediate hold 2
5. Using IL-6 inhibitors in patients with colitis history - intestinal perforation risk 1

The overall incidence of treatment-related adverse events with nivolumab monotherapy is 71%, with grade 3-4 events in only 10% of patients 7. Most toxicities are manageable with established guidelines, and use of immunosuppressive agents does not appear to compromise antitumor efficacy 7.